Type 2 diabetes mellitus (T2DM), affecting approximately 30 million Americans,1 is progressive: treatment intensifies as glycemic control declines, eventually leading to subcutaneous insulin therapy.2 This evidence concerns the gene INS and type 2 diabetes mellitus.